The big pharma has two vaccines that have progressed to late-stage development, one for Clostridium difficile infection and the other for Staph aureus. Both represent big commercial opportunities, but bringing a new vaccine to market is a slow process.
Pfizer Inc. is developing two vaccines in late-stage development that could represent big commercial opportunities – if Pfizer can secure the broad labels it hopes to win.
The two late-stage vaccines Pfizer is focused on are a vaccine for Clostridium difficile infection, which moved into Phase III trials in March, and a vaccine for Staphylococcus aureus in patients undergoing elective surgery in Phase IIb
GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.
Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.
The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.
AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.
Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.
Shares are hit as German conglomerate lowers revenue forecast.
The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.
